Abstract
Tissue norepinephrine content in benign prostatic hyperplasia (BPH) was evaluated to detect possible histological differences in BPH subtypes and to investigate the correlation between norepinephrine levels and age, prostatic weight and clinical symptom score, respectively. Specimens were obtained from 28 patients who underwent transurethral resection of the prostate. Pathologically, 18 out of 28 specimens were classified as fibromyoadenomatous hyperplasia and the remaining 10 as fibromuscular type Norepinephrine content in the fibromyoadenomatous type was 133.1±23.1 ng/g, whereas it was 340.3±60.5 ng/g in the fibromuscular type. Norepinephrine level in the former group was significantly lower than that in the latter group (p<0.001). In both groups, there was no correlation between norepinephrine content, age and clinical symptom score, while the norepinephrine content had a reverse correlation with prostatic weight only in the former group (p<0.05).
In conclusion, norepinephrine levels were dependent upon histological differences, especially upon the amount of smooth muscle elements, in the evaluated specimen. Severity of prostatism and patients' age showed no correlation with tissue norepinephrine content.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Caine, M.: The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy.J. Urol., 136, 1 (1986).
Lepor, H., Gup, D. I., Baumann, M., Shapiro, E.: Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia.Urology, 27, 21 (1988).
Gup, D. I., Shapiro, E., Baumann, M., Lepor, H.: Contractile properties of human prostate adenoma and the development of infravesical obstruction.Prostate, 15, 105 (1989).
Chapple, C. R., Aubry, M. L., James, S., Greengrass, P. M., Burnstock, G., Turner-Warwick, R. T., Milroy, E. G. J., Davey, M. J.: Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation.Br. J. Urol., 63, 487 (1989).
Hedlund, H., Andersson, K.-E., Ek, A.: Effects of prazosin in the treatment of patients with benign prostatic obstruction.J. Urol. 130, 275 (1983).
Kirby, R. S., Coppinger, S. W. C., Corcoran, M. O., Chapple, C. R., Flannigan, M., Milroy, E. J. G.: Prazosin in the treatment of prostatic obstruction: A placebo-controlled study.Br. J. Urol., 60, 136 (1987).
Lepor, H., Auerbach, S., Puras-Baez, A., Narayan, P., Soloway, M., Lowe, F., Moon, T., Leifer, G., Madsen, P.: A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.J. Urol., 148, 1467 (1992).
Hedlund, H., Andersson, K.-E., Larsson, B.: Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate.J. Urol., 134, 1291 (1985).
Lepor, H., Tang, R., Shapiro, E.: The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle.Prostate 22, 301 (1993).
Lepor, H., Tang, R., Meretyk, S., Shapiro, E.: Alpha-I adrenoceptor subtypes in the human prostate.J. Urol., 149, 640 (1993).
Price, D. T., Schwinn, D. A., Lomansney, J. W., Allen, L. F., Caron, M. G., Lefkowitz, R. J.: Identification, quantification, and localization of mRNA for three distinct alpha-1 adrenergic receptor subtypes in human prostate.J. Urol., 150, 546 (1993).
Lepor, H., Shapiro, E., Bowsher, R. R., Henry, D. P.: Determination of norepinephrine levels in the adult human prostate.J. Urol., 144, 1263 (1990).
Vaalasti, A., Hervonen, A.: Autonomic innervation of the human prostate.Invest. Urol., 17, 293 (1980).
Barry, M. J., Fowler, F. J., O'Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., Cockett, A. T. K. and the Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia.J. Urol., 148, 1549 (1992).
Roehrborn, C. G., Chinn, H. K. W., Fulgham, P. F., Simpkins, K. L., Peters, C. P.: The role of transabdominal ultrasound in the preoperative evaluation of patients with benign prostatic hypertrophy.J. Urol., 135, 1190 (1986).
Wagner, J., Vitali, P., Palfreyman, M. G., Zraika, M., Huot, S.: Simultaneous determination of 3,4-dihydroxyphenylalanine, 5-hydroxytryptophan, dopamine, 4-hydroxy-3-methoxyphenylalanine, nor-epinephrine, 3,4-dihydroxyphenyl acetic acid, homovanillic acid, serotonin, and 5-hydroxyindoleacetic acid in rat cerebrospinal fluid and brain by high-performance liquid chromatography with electrochemical detection.J. Neurochem., 38, 1241 (1982).
Nakada, T., Furuta, H., Katayama, T.: Catecholamine metabolism in pheochromocytoma and normal adrenal medulla.J. Urol., 140, 1348 (1988).
Franks, L. M.: Benign prostatic hyperplasia: Gross and microscopic anatomy. In: Grayhack, J.T., Wilson, J. D., Scherbenske, M. J. (eds): Benign Prostate Hyperplasia, p. 63. NIAMDD Workshop Proceedings, DHEW Publication No. (NIH) 76-1113 (1976).
Baumgarten, H. G., Falck, B., Holsten, A.-F., Owman, Ch., Owman, T.: Adrenergic innervation of the human testis, epididymis, ductus deferens and prostate: A fluorescence microscopic and fluorimetric study.Z. Zellforsch., 90, 81 (1968).
Gup, D. I., Shapiro, E., Baumann, M., Lepor, H., Autonomic receptor in human prostate adenomas.J. Urol., 143, 179 (1990).
Shapiro, E., Hartanto, V., Lepor, H.: The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle.Prostate, 21, 297 (1992).
Siegel, Y. I., Zaidel, L., Hammel, I., Korczak, D., Linder, A.: Morphometric evaluation of benign prostate hyperplasia.Eur. Urol., 18, 71 (1990).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ishigooka, M., Hayami, S., Tomaru, M. et al. Norepinephrine contents of human prostatic hyperplasia: Differences between pathological subtypes. International Urology and Nephrology 28, 61–66 (1996). https://doi.org/10.1007/BF02550139
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02550139